Skip to main content
Premium Trial:

Request an Annual Quote

IP Watch: Diagnoplex, BioMérieux, Fluidigm, Quest, Others Win US Patents


The Regents of the University of California have been awarded US Patent No. 8,697,348, "Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571."

Charles Sawyers, Mercedes Gorre, Neil Shah, and John Nicoll are named as inventors.

Diagnoplex has been awarded US Patent No. 8,697,350, "Biomarker combinations for colorectal cancer."

Curzio Ruegg, Sylvain Monnier-Benoit, Laura Ciarloni, and Stavros Therianos are named as inventors.

BioMérieux has been awarded US Patent No. 8,697,352, " Nucleic acid sequences that can be used as primers and probes in the amplification and detection of all subtypes of HIV-1."

Jaap Goudsmit, Pieter Oudshoorn, Suzanne Jurriaans, and Vladimir Lukashov are named as inventors.

Japan Advanced Institute of Science and Technology has been awarded US Patent No. 8,697,357, "Method for detection of methylcytosine using photoresponsive probe."

Kenzo Fujimoto, Masayuki Ogino, and Yuta Taya are named as inventors.

Technische Universitaet Dresden has been awarded US Patent No. 8,697,358, "Non-invasive method for diagnosis of prostate cancer."

Manfred Wirth, Susanne Fuessel, and Rainer Koch are named as inventors.

Caliper Life Sciences (PerkinElmer) has been awarded US Patent No. 8,697,362, "Methods of detecting low copy nucleic acids."

Michael Knapp, Jill Baker, Andrea Chow, Anne Kopf-Sill, and Michael Spaid are named as inventors.

Fluidigm has been awarded US Patent No. 8,697,363, "Methods for detecting multiple target nucleic acids in multiple samples by use nucleotide tags."

Alain Mir, Ramesh Ramakrishnan, Marc Unger, and Bernhard Zimmermann are named as inventors.

Quest Diagnostics and US Genomics have been awarded US Patent No. 8,697,399, "Nucleic acid size detection method."

Donghui Huang, Charles Strom, Steven Potts, and Jenny Rooke are named as inventors.

Shimadzu Corporation has been awarded US Patent No. 8,697,400, "Method for amplification of DNA from blood sample and DNA amplification kit therefor."

Masamitsu Shikata is named as the inventor.

New England Biolabs has been awarded US Patent No. 8,697,408, "Ligation enhancement."

Rebecca Kucera and Thomas Evans, Jr. are named as inventors.

ZS Genetics has been awarded US Patent No. 8,697,432, "Systems and methods of analyzing nucleic acid polymers and related components."

William Glover, III is named as the inventor.

Samsung has been awarded US Patent No. 8,697,433, "Polymerase chain reaction module and multiple PCR system using the same."

Kwang-wook Oh, Jin-tae Kim, Kak Namkoong, Chin-sung Park, and Yoon-kyoung Cho are named as inventors.

E. I. du Pont de Nemours and Company has been awarded US Patent No. 8,697,852, "Genetic fingerprinting and identification method."

Frank Burns and Xuan Peng are named as inventors.

The President and Fellows of Harvard College have been awarded US Patent No. 8,698,481, "High-resolution molecular sensor."

Charles Lieber, Qihua Xiong, Ping Xie, and Ying Fang are named as inventors.

Koninklijke Philips has been awarded US Patent No. 8,700,381, "Methods for nucleic acid quantification."

Josephus Kahlman, Bin Yin, and Tamara Nijsen are named as inventors.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.